[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100069291":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":17,"collaborators":7,"id":19,"slug":20,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":27,"maxAge":7,"enrollmentInfo":28,"targetDuration":7,"studyType":31,"phases":32,"briefSummary":34,"conditions":35,"keywords":37,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Oxcarbazepine",[13],{"name":14,"affiliation":15,"role":16},"Eduard Vieta, MD","Hospital Clinic, Universitary of Barcelona","PRINCIPAL_INVESTIGATOR",{"type":18,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100069291","phase-4-the-efficacy-and-safety-of-oral-oxcarbazepine-300-1200-mgday-as-adjuvant-therapy-in-the-treatment-of-bipolar-disorder-i-or-ii-this-study-is-not-being-conducted-in-the-united-states-100069291",false,"NCT00154323","The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg\u002FDay as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.","A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg\u002FDay) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment","Inclusion Criteria:\n\n* History of bipolar disorder type I or II\n\nExclusion Criteria:\n\n* Other serious medical conditions\n* Treatment with antiepileptic medications\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":29,"type":30},55,"ACTUAL","INTERVENTIONAL",[33],"PHASE4","Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania, grandiose delusions, and suicidality. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with bipolar disorder type I or II.",[36],"Bipolar Disorder",[38],"Oxcarbazepine, bipolar disorder","COMPLETED","2023-12-13",{"date":42,"type":30},"2023-12-14",{"date":44,"type":7},"2003-01",{"date":46,"type":30},"2006-01",{"name":5,"class":6}]